Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting
Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting |
| [23-September-2026] |
SAN FRANCISCO and SUZHOU, China, Sept. 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that clinical data for its IBI363/TAK-928 (PD-1/IL-2α-biased bispecific fusion protein) * , IBI343/TAK-921 (Arcotatug Tavetecan, CLDN18.2 ADC) *, IBI3001(EGFR/B7H3 ADC) * , IBI354(HER2 ADC) and TYVYT® (sintilimab injection)** will be presented at the 2026 European Society For Medical Oncology (ESMO) Annual Meeting from Oct 23 to Oct 27, 2026, in Madrid, Spain. In particular, the results from a registrational Phase 3 clinical trial (G-HOPE-001) of IBI343/TAK-921 (Arcotatug Tavetecan, CLDN18.2 ADC) * has been accepted for Late-Breaking Abstract (LBA) and will be orally presented during the ESMO proffered paper session. Dr. Hui Zhou, Chief R&D Officer (Oncology) of Innovent, stated: "At the 2026 ESMO Annual Meeting, we will publish the registrational Phase 3 data for the globally advanced Arcotatug Tavetecan (CLDN18.2 ADC) in third‑line gastric cancer through LBA. We will also present additional data from IBI363 studies in NSCLC and preliminary data in first-line gastric cancer, further validating its broad potential as a next-generation immuno-oncology therapy. In addition, we will unveil global multicenter Phase 1 data for the first-in-class IBI3001 (EGFR/B7H3 ADC) for the first time, as well as Phase 2 data for the potentially best-in-class IBI354 (HER2 ADC) in first-line breast cancer. Innovent remains committed to pushing the boundaries of cancer treatment and delivering more innovative, effective, and potentially life-saving therapeutic options to physicians and patients." Abstracts of Next-gen IO+ADC Pipeline 1. Presentation Title: Arcotatug Tavatecan (IBI343/TAK-921) versus treatment of physician's choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G-HOPE-001 study Final Publication Number: LBA77 2. Presentation Title: IBI363 (TAK-928) plus chemotherapy as first line (1L) treatment for advanced non-small cell lung cancer (NSCLC): Update of a phase 1b study Final Publication Number: 1044P 3. Presentation Title: IBI363 (TAK-928) plus XELOX as the first line (1L) treatment for advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA)** Final Publication Number: 1008RO 4. Presentation Title: IBI363 (TAK-928) plus bevacizumab (Bev) vs docetaxel (DTX) in patients (pts) with locally advanced or metastatic immunotherapy (IO)-resistant lung adenocarcinoma (LUAC) without actionable genomic alterations: a randomized phase Ib study Final Publication Number: 1952RO 5. Presentation Title: Safety and efficacy of IBI3001, an anti-EGFR/B7H3 bispecific ADC, in patients (pts) with advanced solid tumors: Results of a multi-regional phase 1 study Final Publication Number: 1001O 6. Presentation Title: IBI354 plus pertuzumab as first-line (1L) treatment for patients (pts) with HER2-positive, unresectable locally advanced or metastatic breast cancer (BC): Results from a phase 2 study Final Publication Number: 1776P Abstracts of TYVYT®(sintilimab) 1. Presentation Title: Under the neoadjuvant chemoimmunotherapy strategy, reducing the cycles of chemotherapy may yield similar efficacy to the standard treatment model: a randomized, non-controlled cohort study on resectable non-small cell Iung cancer Abstract Number: 6528 2. Presentation Title: Sintilimab combined with bevacizumab and induction chemotherapy in the treatment of N2-3 nasopharyngeal carcinoma: A Prospective, single-arm, multicenter phase ll clinical study Abstract Number: 2868 3. Presentation Title: Sintilimab in combination with Cetuximab and Chemotherapy as first-line treatment for MSS/pMMR and RAS/BRAF wild-type metastatic colorectal cancer (CALLIOPSIS): a phase Ib/II dose escalation and expansion trial Abstract Number: 4276 4. Presentation Title: Efficacy of Fruquintinib Plus Sintilimab in Special Populations with Advanced Renal Cell Carcinoma: A Subgroup Analysis of FRUSICA-2 Study Abstract Number: 3367eP 5. Presentation Title: Association between dose adjustment and treatment outcomes in patients with advanced renal cell carcinoma receiving Fruquintinib plus Sintilimab: A post-hoc analysis of the FRUSICA-2 trial Abstract Number: 3655eP 6. Presentation Title: Efficacy and safety of IBI351 plus cetuximab β±FOLFIRI inpatients with KRAS G12C-mutated metastatic colorectal cancer (the CRUCIAL study) Abstract Number: 885eP
About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset under NMPA review, 5 assets in phase 3 or pivotal clinical trials, and 19 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.
SOURCE Innovent Biologics | |||||||
Company Codes: HongKong:1801 |
View original content:
